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A B S T R A C T
Objectives: To estimate the risk of seizure recurrence after antiepileptic drugs (AED) withdrawal and to
identify related predictive features in patients with idiopathic generalized epilepsy (IGE) commencing at
developing age (up to 16 year).
Methods: Medical records of consecutive patients with IGE from two refferal hospitals were evaluated
between 2001 and 2009. Inclusion criteria were clinical and EEG diagnosis of IGE and follow up for at
least 2 years after the AED withdrawal. The cohort consisted of 59 patients (38 females, 21 males). Follow
up after withdrawal lasted 2–10 years (median 3) Time to seizure relapse and predictive factors were
analyzed by survival methods.
Results: There were 21 (35.6%) patients with childhood absence epilepsy (CAE), 11 (18.6%) with juvenile
absence epilepsy (JAE), 10 (16.9%) with isolated primary GTC seizures, and 17 (28.8%) with juvenile
myoclonic epilepsy (JME). The relapses occured in 23 (52.2%) patients: one (6.2%) with CAE, 4 (50%) with
JAE, 8 (80%) with IGE with GTC seizures and all with JME. During the ﬁrst 6 months 54.5% patients relapsed
(20% during withdrawal), 63.6% within 12 months, 81.8% within18 months and 95.4% within 24 months
after withdrawal. Female gender, age at onset of seizures, seizure types, EEG worsening during/after AED
withdrawal and age at withdrawal were signiﬁcantly associated with relapse risk according to univariate
analysis. In multivariate analysis, retained signiﬁcant factors were: seizure types and EEG worsening.
Conclusion: Diagnosis of the speciﬁc IGE syndrome strongly affects relapse rate: the lowest was in CAE,
the highest in JME. Independent risk factors for seizure relapse were: seizure type and EEG worsening
during and/or after withdrawal.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
The impact of idiopathic generalized epilepsy (IGE) is estimated
to be about 15–20% of all epilepsies.1 The present International
League against Epilepsy/ILAE/classiﬁcation2 recognizes several
epileptic syndromes within IGE group. The proposed and revised
classiﬁcation further evolves the spectrum of IGE introducing new
syndromes in development.3
Dynamic evolution of the known IGE syndromes and their
frequent overlap often impose difﬁculties in determining speciﬁc
IGE type in an individual patient at the disease onset as well as its
prognosis.
Prognostic aspects of IGE treatment have been rarely evaluated
in the literature. It is largely recognized that most of patients with
IGE have good seizure control while on antiepileptic drug (AED)
but uncertain prognosis after its withdrawal. In addition, there
have not been randomized trials addressing in particular the
optimal length of IGE treatment.* Corresponding author. Tel.: +381 63 8652518.
E-mail address: milen_p@ptt.rs (M. Pavlovic´).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.03.007The decision about when and whether to attempt AED
withdrawal during clinical remission is an old known dilemma
facing both patients and clinicians. Numerous studies on AED
withdrawal, have usually estimated relapse risks in heterogeneous
patient cohorts regarding the type and etiology of epilepsy. Only a
few studies encompassed the issues of risk of seizure recurrence
after AED withdrawal in patients with different types of IGE.4–8 So
far, apart from clinical experience, no clear guidelines were given
in order to answer the question of proper timing and safety of AED
withdrawal in children and adolescents within particular IGE
syndrome.
The main obstacle in the assessment of IGE prognosis in young
patients while on treatment is the lack of reliable outcome
associated predictors. Therefore, this study was aimed to estimate
the relapse risk after AED withdrawal in children and adolescents
up to 16 years of age, with different types of IGE and to identify
factors predictive of seizure relapse.
2. Patients and methods
The study was conducted from June 2001 through December
2009. Subjects were identiﬁed among consecutive patients fromvier Ltd. All rights reserved.
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Adolescents Health Care in Novi Sad and Clinic for Neurology and
Psychiatry for Children and Youth in Belgrade, Serbia (85 km apart
from each other). Subjects as outpatients were seen by neurol-
ogists and/or neuropediatricians/epileptologists in the follow up
intervals of 3–6 months, until the end of studied period.
Inclusion criteria were: diagnosis of IGE according to the ILAE
criteria,2 established clinical remission of at least two years before
AED withdrawal and clinical follow up for at least two years after
withdrawal or until seizure relapse. Patients were not eligible for
the study if there was any doubt over the diagnosis on clinical
grounds, or if all needed relevant data were not available from the
case history notes. Patients who dropped out of the follow up from
different reasons – non-responders or attending other Clinics were
not included. For two patients, exact time of seizure relapse could
not be determined.
Medical records of patients coded as IGE were evaluated during
the observational period. The primary outcome end-point was
seizure recurrences after the AED discontinuation. Withdrawal of
AED was gradually performed in variable periods with duration
ranged from 6 to 12 months.
The following variables, derived from the case records were
analyzed: aside from the basic demographic ones (age and sex), age
at seizure onset, type of seizure, cognitive and neurological status,
history of status epilepticus, EEGs registered before, during and
after AED withdrawal, records of focal EEG features, photo-
paroxysmal response to intermittent photo-stimulation, AED in
monotherapy vs. polytherapy, length of AED therapy, duration of
the clinical remission (seizure freedom) while on AED, age at AED
withdrawal, history of febrile seizures, family history for epilepsy,
prenatal and/or perinatal complications and history of co-morbid
pediatric disorders. These variables entered computerized data-
base formed for all out-patients regularly examined.
3. Patient characteristics
During the investigation period, 59 patients who met all
inclusion criteria were identiﬁed: females 22 (37.3%), males 37
(62.7%). The age of seizure onset was in range 4.5–16 years
(median 10). At the end of the observational period the age of
patients was in range 11–36 years (median 18). The duration of the
follow-up since AED withdrawal in the whole group was in range
2–10 years (median 3).
Patients were classiﬁed in regard to the epilepsy syndromes.
The distribution was as follows: childhood absence epilepsy (CAE)
in 21 (35.6%) patients; juvenile absence epilepsy (JAE) in 11 (18.6%)
patients, epilepsy with primary GTC seizures in 10 (16.9%) patients,
and juvenile myoclonic epilepsy (JME) in remaining 17 (28.8%)
patients.
All patients had normal neurological examination and neuro-
imaging (CT/MRI) ﬁndings. Cognitive status was normal in most of
the patients (three patients had mild cognitive impairment).
Regarding the AED therapy before withdrawal, 95.3% of patients
with IGE were on monotherapy by valproic acid. The other drugs
used in remaining 4.7% patients were ethosuximide and clonaze-
pam. The AED therapy duration was in range 1–9 years (median 4).
The length of stable clinical remission while on AED was in range
2.5–9 years (median 4). The age at AED withdrawal was in range 9–
25 years (median 14.25).
Not any patient had the history of status epilepticus. No
patients had previously suffered febrile seizure. Family history of
epilepsy was noted in 11 (25%) of patients: ﬁrst-grade relatives
(parents and siblings) in 5 patients, second degree relatives in 5
and both degrees in one case. Pregnancy was hormonally
maintained in 13% of patients. Birth was normal in all cases.Analysis of somatic co-morbidities disclosed four patients with
asthma.
EEG in both settings was recorded according to the interna-
tional 10–20 electrode placement system (21 channel) using
Oxford Medilec EEG machine. Video-EEG become available for
5 years ago and since then it has been used as routine monitoring.
Combined awake–sleep EEG was the established procedure for the
AED withdrawal procedure monitoring. Awake EEG included
activation procedures: hyperventilation of 3–5 min and intermit-
tent photic stimulation. The latter was performed with strobo-
scopic ﬂash at 1–30 Hz by using a light source placed 20–30 cm in
front of the patients eyes. Sleep EEG was recording during
spontaneous sleep or after the one night of sleep deprivation
(the evening before recording) or following a partial sleep
deprivation (3–4 h) the night before.
The following EEG features were registered: generalized
epileptiform activity, focal epileptiform activity, abnormal activity
other than epileptiform as well as photic paroxysmal reponse (PPR)
if present. For the purpose of the study, records were classiﬁed, as
abnormal if EEG included unequivocal epileptiform abnormalities
and non-epileptiform/non-speciﬁc/abnormalities, regardless of
the vigilance state during recording. If EEG recording showed
the reappearance of abnormalities (spikes, spike-waves dis-
charges, slow waves paroxysms), EEG record was marked as
worsened. EEG records were performed at least once during the
withdrawal period and every 3–6 months in the post withdrawal
follow-up period.
4. Statistical analysis
SPSS software package for statistical analysis was used. As the
main outcome measure was seizure relapse, time to seizure relapse
was analyzed by Kaplan Meir method to illustrate the likelihood of
seizure recurrences. Factors of possible prognostic values were
evaluated by x2 test. Relative risks for recurrence during the
follow-up were investigated by Cox regression analysis – uni/
multivariate analyses9 to allow for variable length of follow up.
Outcome predictive factors were modeled according to the hazard
ratio/HR/followed by the 95% conﬁdence interval/CI. Statistical
signiﬁcance was accepted at p < 0.05.
5. Results
During the investigation period, 23 (38.9%) patients relapsed
(15 had GTC type of seizure, 6 had myoclonic and 2 had combined
myoclonic and absence types of seizures). In 15 (25.8%) patients
EEG worsening, i.e. reappearance of epileptiform abnormalities
after AED withdrawal occurred: in 5 patients with CAE, 3 with JAE
and 7 with JME. That EEG aggravation was followed by the AED
reintroduction. In the remaining follow up period, along with
noted EEG improvement, no relapses occurred.
This group of patients, therefore, was excluded from the
estimation of risk for seizure recurrence. Upon exclusion of this
group of patients, seizure relapse occurred in 52.2% of the 44
patients remaining for further investigation. The Fig. 1 presents all
outcome varieties after the AED withdrawal.
Regarding the recognized IGE syndrome, distribution of
relapses was as follows (Table 1): CAE: only one out of 16
investigated patients with CAE (6.25%), 4 out of 8 patients with JAE
(50%), 8 out of 10 patients with IGE with GTC seizures (80%) and all
patients with JME (100%).
Most relapses occurred during the ﬁrst year since the AED
withdrawal: 54.5% patients relapsed during the ﬁrst 6 months (20%
of them during the AED withdrawal), 63.6% patients within 12
months, 81.8% within 18 months and 95.4% within 24 months, as
shown at Fig. 2 and corresponding Table 2.
Table 1
Seizure recurrences related to the IGE syndrome.
IGEa syndrome Patients
Total no Excluded due to AED reintroduction Investigated (females/males) Relapsed (females/males)
Childhood absence epilepsy 21 5 16 (8/8) 1 (1/0)
Juvenile absence epilepsy 11 3 8 (7/1) 4 (4/0)
Epilepsy with GTCb seizures 10 0 10 (8/2) 8 (7/1)
Juvenile moclonic epilepsy 17 7 10 (6/4) 10 (6/4)
Total 59 15 44 (29/15) 23 (18/5)
a IGE, idiopathic generalized epilepsy.
b GTC, generalized tonic–clonic.
Fig. 1. All outcome varieties after the AED withdrawal.
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Fig. 2. Cumulative probability of stable seizure freedom following the AED
withdrawal as a function of time (months) shown as Kaplan–Meier survival curve
(indicating the interval between AEDs withdrawal and seizure relapse). Time 0
means the beginning of AED withdrawal.
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for the main variables investigated are shown at Table 3. There
were no signiﬁcant differences between relapsed and non relapsed
groups for: cognitive status, EEG record before withdrawal, focal
EEG abnormalities and PPR in EEG records, duration of AED
therapy, duration of seizure freedom on AED, perinatal history and
family history of epilepsy. Regarding EEGs before the discontinua-
tion of AEDs, of those who relapsed, only 3 patients had EEG
abnormalities before withdrawal, including two patients with IGE
with GTC seizures and one patient with JME. All patients with
absence epilepsies (one patient with CAE and four patients with
JAE) who relapsed had normal EEG before the AED withdrawal. TheTable 2
Distrubution of relapses incidence during the follow up after withdrawal.





25–45 1 100.0remaining 20 patients who relapsed had normal EEG records
before the AED discontinuation.
The risk factors found to signiﬁcantly affect relapse risk
according to the univariate analysis were, as shown at the Table
4: female sex, age at seizure onset above 10 years, type of seizures
(GTC and mixed types), abnormal EEG during/and/or after AED
withdrawal and age of AED withdrawal above 15 years.
Multivariate analysis was applied in order to investigate the
simultaneous inﬂuence of several factors on the relapse rate. EEG
worsening during and after the AED withdrawal as well as type of
seizures (GTC and combination of GTC seizures with myoclonic or
absence seizures) was found to be independent risk factors in
predicting the relapse risk (Table 5).
6. Discussion
Numerous studies of AED withdrawal, published so far, are
mostly based on heterogeneous cohorts, consisting largely of
patients with partial epilepsies.10 There has not been a single study
of that design, speciﬁcally addressed to patients with IGE having
onset at developing age. Therefore, the data will be discussed in the
frame of only selected relevant results from some studies.
6.1. Overall relapse rate
The rate of seizure relapses as the main outcome measure in the
follow up cohorts was commonly compared among the various
studies of AED withdrawal. The total relapse rate (51.2%) in this
study group was higher than average ones, usually cited in AED
withdrawal studies (about 30%).12 In the study of Nicolson et al.,6
the largest outcome study of IGE performed so far, there was also
the high rate of relapses (79.9%). The study pointed that the
majority of investigated patients were adults, and at least some of
them might have IGE with onset in the developmental age.
6.2. Syndrome related relapse rate
Regarding particular, epileptic syndrome-related relapse rates,
there were relatively small subgroups of patients available for
statistical estimation. In our study, the lowest relapse rate (6.2%)
Table 3
Possible risk factors and corresponding relapse rate.
Variable Total (N) Total (%) Relapse (N) Relapse (%) p
Gender
Female 29 65.1 18 62.1
Male 15 34.9 5 33.3 0.01
Age at epilepsy onset (years)
<10 22 50.0 5 22.7 0.001
>10 22 50.0 18 81.8
Type of seizure
Absence 19 43.2 2 10.5 0.001
GTC 18 41.0 14 77.7
Combinedb 7 15.8 7 100.0
Cognitive status
Impaired 3 6.8 1 33.3 NSa
Normal 41 43.2 22 53.6
EEG before withdrawal
Normal 37 84.1 20 54.1 NS
Abnormal 7 15.9 3 42.8
EEG during/after withdrawal
Normal 28 63.6 12 42.8 0.011
Abnormal 16 36.4 11 68.7
Focal EEG abnormalities
Yes 5 12.3 4 80.0 NS
No 39 88.6 19 48.7
PPRc
Yes 16 36.4 10 62.5 NS
No 28 63.6 13 46.4
AED therapy
Monotherapy 42 95.5 21 50.0 NS
Polytherapy 2 4.5 2 100
Duration of AED therapy (years)
<4.5 26 59.1 14 53.84 NS
>4.5 18 41.9 9 50.0
Seizure freedom on AED therapy (years)
<4 25 56.8 14 56.0 NS
>4 19 43.2 9 44.0
Age at withdrawal (years)
<15 24 54.5 8 33.3 0.01
>15 20 45.5 15 75.0
Perinatal history
Normal 6 13.7 4 75.0 NS
Abnormal 38 86.3 19 50.0
Family history of epilepsy
Yes 11 25.0 6 54.5 NS
No 33 75.0 17 51.5
a NS, non-signiﬁcant.
b Combined GTC with absence and/or myoclonic seizures.
c PPR, photic paroxysmal response.
Table 5
Signiﬁcant predictors of seizure relapse according to multivariate analysis.
Variable HR (95% CI)a p
++G worsening (reappearance of epileptifom
discharges) during and/or after withdrawal
4.00 (1.39–11.5) 0.01
Gype of seizure (GTCS and combined GTCS
with myoclonic or absance seizures)
2.12 (1.13–4.3) 0.02
a HR, hazard risk; CI, conﬁdence interval.
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prospective study conducted by Wirrel8 in a subgroup of 59
patients, whose epilepsy began with absence seizures, 20.3% of
patients relapsed after the AED withdrawal. The relapses were
considered as being result of CAE evolution to other types of IGE/7%
to JME and 15% to JME. In the study of Covanis et al.,11 13 patients
(31.5%) relapsed from 41 cases with absences who discontinued
AED. At least 3 of them were considered as being evolved into JME.
In our study, from 24 patients total with absence seizures (CAE plus
JAE patients) only one patient of 16 belonging to CAE relapsed. In
the smaller group of 8 patients with JAE, 4 patients relapsed. Taken
together, the relapses ocurred in 20.8% with absence epilepsies,Table 4
Signiﬁcant predictors of seizure relapse according to univariate analysis.
Variable HR (95% CI)a p
Female sex 2.59 (1.21–5.21) 0.01
Age at seizure onset >10 years 4.37 (2.02–4.4) 0.001
++G worsening during/after AED withdrawal 4.67 (1.08–12.01) 0.01
Gype of seizureb 2.17 (1.7–2.7) 0.02
Age at AED withdrawal > 15 years 2.64 (1.4–5.0) 0.02
a HR, hazard risk; CI, conﬁdence interval.
b GTC seizures and combined GTC seizures with myoclonic or absence seizures.which correlates approximately well with the results of mentioned
studies.8,11 In adittion, from 17 of our patients with JME there were
2 with a history of earlier absence seizures. These patients might be
also regarded as cases presenting evolution from CAE to JME. Thus,
these and previously reported data, favoure the view that such
evolutive course is hard to predict at the time of diagnosis. In other
words,remission could be predicted only by the course of epilepsy.
An interesting aspect of the issue was offered by Grosso et al.4
who pointed that implementation of different criteria in classiﬁ-
cation of CAE (ILAE criteria vs. more strict criteria deﬁned by
Panayotopoulos) leads to different estimations concerning CAE
outcome: AED withdrawal in the ﬁrst case led to the relapses in
22% patients, while no one relapsed in the other case. More strict
criteria were in favour of excellent prognosis for CAE. Although
based on ILAE criteria, our patients with CAE had favorable
outcome at the end of the follow up. However, the study of
Nicolson et al.6 of mainly adult patients reported pretty higher
relapse rate for patients with CAE (65.5%).
According to the rare reports of the long-term follow up of JAE
patients,13–15 this IGE syndrome seems to have an overall lower
rate of long-term remission. Our study with a small subgroup of
patients pointed to the equivocal results (50% relapsed). This
correlates with the results of Covanis et al.11 where 3 out of 5
patients with JAE relapsed after AED withdrawal. Nicolson et al.6
reported similar relapse rate of 68.4%. As far as IGE subgroup with
GTC seizures is concerned, 8 out of 10 patients relapsed. No
partcular attention regarding their prognosis has been observed in
published literature. Maybe, the reason could be in perception that
this group rather belongs to overlapping continuum of IGE
syndromes. So, deﬁnitive prospect from the view of developmental
period stand point is not easy to anticipate.
In our study, all studied patients with JME who discontinued
AED relapsed after AED withdrawal. General impression from the
published literature regards JME15–18 as the life long epileptic
condition. Canevini et al. reported relapses in all JME patients
attempted to discontinue AED19. In some studies6,20 the relapse
rate following AED withdrawal was 93.6% and 81.8% respectfully.
Considering the relapse rate for JME patients in our cohort, we
were not aware what could happen to those patients who restarted
AED after worsening of EEG only and without seizure relapse.
The time of relapses: most of the recurrences in our study
occurred within the ﬁrst two years (95.4%). More than a half of
these relapses (54.5%) occurred during the ﬁrst 6 months, and
18.8% during the withdrawal period. This is in concordance with
previous works on overall timing of relapse in heterogeneous study
groups: 85–90% of recurrences occurred within 2 years,7,18,21 in
particular during AED withdrawal and in the course of the ﬁrst few
months after discontinuation of therapy. That further supports the
need for clinical and EEG follow up of these patients for at least
during the ﬁrst 2 years after AED withdrawal.
6.3. Risk factors for relapse
In comparison to factors predictive of relapses after AED
withdrawal in epilepsies of non-idiopathic etiology, the investi-
gated variables spectrum is obviously reduced (neurological status
and neuroimaging ﬁndings in IGE were normal and therefore
M. Pavlovic´ et al. / Seizure 20 (2011) 520–525524excluded). In the investigated cohort of IGE patients, according to
univariate and mutlivariate analysis, seizure type/GTC and mixed
types of seizure (GTC combined with myoclonic and/or absence
seizures)/and interictal EEG worsening during/after AED with-
drawal were associated with signiﬁcantly increased risk of seizure
relapses on the follow-up.
The marked inconsistencies reported in the literature regarding
the effect of seizure type on withdrawal outcome can be mostly
attributed to the differences in studied population. GTC seizures
during the course of disease are highlighted as signiﬁcant predictor
of adverse outcome in some studies,4,13,14 which is concordant
with the results of our study. In 4 out of 6 patients in our study,
who had GTC seizures apart from absence seizures, relapses
ocurred. These patients belonged to the JAE subgroup of patients.
The long-term prognosis of this IGE syndrome was the topic of only
a few studies designed not as withdrawal studies but as general
outcome studies.12–14 The results of the study conducted by Grosso
et al.4 are also in corelation to our results: the most important
independent predictors of remission failure (deﬁned as no seizures
after withdrawal for more than one year) were GTC seizures and
myoclonic seizures during the active disease.
Our study pointed to the importance of EEG worsening during
withdrawal and after the AED withdrawal, as a solid marker for
those who will relapse without medication. On the other side,
inter-ictal EEG records before the AED discontinuation were not
predicting for relapse. Of 23 patients who relapsed, 3 (13%)
patients had EEG abnormalities before withdrawal. Reported
effects of abnormal EEG prior to the AED withdrawal on relapse
risk are otherwise, extremely inconsistent in the published
literature.21,22 However, results of this study indicated an
association between EEG worsening (persisting and/or increased
interictal epileptiform abnormalities during/after AED withdraw-
al) as statistically signiﬁcant. This is similar with results of the
study conducted by Galimberti et al.,23 which enrolled adult
patients. !ndersson et al.24 reported that persistence of general-
ized paroxysms of spike-waves predicted relapses during AED
withdrawal. These discharges are otherwise supressed during
treatment, especially in children with absence seizures before AED
withdrawal. Olsson et al.25 did not recommend AED withdrawal in
patients with absence seizures as far as abnormal EEG exist.
Because spike-wave paroxisms may persist during maintained
clinical remission, or GTC seizures may ocurr in the absence of
interictal EEG abnormalities, predictive value of EEG is relativ-
ized.25,26 Possible inﬂuence of residual SW discharges to the
outcome of epilepsy was also emphasized in the work of
Camﬁelds.27 They warranted repeating EEG after the AED
discontinuation in order to look for reappearance of epileptiform
discharges. This is in accordance to our study where in 5 of our
patients with CAE and in 3 patients with JAE alarming presence of
interictal spike-waves prompted reintroduction of AED.
Female gender was one of the signiﬁcant predictors for relapse
risk according to the univariate analysis. Higher relapse rate in girls
was also found in studies of Altunbasak et al. and Dooley et al.21,28
This ﬁnding is probably reﬂection of female predominance over
males in the study cohort especially regarding subgroups of patients
with less favorable outcome/IAE, IGE with GTC seizures and JME.
Relapse risk in females could also be affected by physiological
hormonal disturbances related to the age at disease onset and the
age of AED withdrawal. These are two further commented variables,
signiﬁcantly associated with relapse risk in the univariate analysis.
Age at seizure onset beyond ten years of age, as the important
predictor for relapse found in this study is concordant with some
earlier studies.28,29 It also correlates with poorer outcome of those
IGE syndromes commencing at that age. Age of AED withdrawal, as
also one of the signiﬁcant variables associated with higher relapse
risk, not unexpectedly, mirrored the previous ﬁnding.Whether duration of AED treatment changes the prognosis of
epilepsy or simply suppresses seizures to allow the spontaneous
remission? This topic has been debated intensely. 12,22,27 Duration
of AED therapy for less than 4.5 years was not signiﬁcantly
associated with relapse risk in the univariate analysis of our study,
such not supporting the view that longer period of AED treatment
enables safer discontinuation.
The study faced some limiting issues. Enrolment of sufﬁcient
number of patients was inﬂuenced by the actual representation of
this type of epilepsy in the regions covered by two hospitals where
investigation was conducted. Better recruitment so appeared more
likely, although some patients followed by other physician at these
settings might be missed. In addition, selection of patients for
withdrawal of antiepileptic treatment could be biased by personal
attitudes related to issues such as length of treatment and/or EEG
precluding criteria.
7. Conclusion
Applying the common design of most AED withdrawal studies,
this study was aimed to identify predictors of the outcome in
patients with IGE when discontinuation of drugs is considered.
Given the overlapping of syndromes within IGE throughout their
natural history, the task was challenging.
The study results underlined the importance of syndromic
attributes of speciﬁc IGE for assessing outcome after the AED
withdrawal: the lowest relapse risk being in CAE and highest in
JME. However, as this clear cut distinction of syndromes seems not
to be always obvious at the very beginning of the disease course,
knowledge of the outcome predictors could guide clinicians in a
safer mode. A few prognostic factors, as independent variables
emerged as valuable for the prediction of seizure recurrence in IGE:
EEG worsening during and/or after the AED withdrawal and history
of GTC seizures alone or in combination with other generalized
seizures. Larger longitudinal studies in future, might give
additional support to these data, especially in assessing the risks
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